Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab monotherapy in adults with severe alopecia areata
2024-511225-64-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of amlitelimab in alopecia areata (3 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in SALT score at Week 36. Started Aug 2024; status: completed.
02
Drugs
amlitelimab
03
Conditions
alopecia areata
Beyond the preview
Go deeper on 2024-511225-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511225-64-00.